© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
December 01, 2014
Treatment with a combination of tenofovir and pegylated interferon yielded higher rates of hepatitis B surface antigen (HBsAg) loss than when either drug was used singly. Further, with longer therapy duration improved results.
November 17, 2014
Recent updates by the 8th Joint National Committee (JNC 8), the American and International Societies of Hypertension (ASH-ISH), and KDIGO recommend target blood pressure of less than 140/90 mm Hg for most individuals, including those with CKD.
Two major sets of hypertension guidelines released in 2014 contain more common threads than differences, and are intended to serve different purposes. Clinicians seeking guidance for managing hypertension in chronic kidney disease (CKD) can look for this common ground to avoid "guideline overload."
Guidelines for hypertension have converged on a blood pressure target of less than 140/90 mm Hg for most individuals with chronic kidney disease (CKD). However, studies still need to clarify optimal BPs for advanced disease and optimal cardiovascular prevention.
Increased Risk of Eating Disorders, ARFID Among Cystic Fibrosis Population
Sleep Disorder May Increase Short-Term Risk for Late-Onset Dementia
FDA Approves Baloxavir Marboxil to Treat, Prevent Flu in Younger At-Risk Children